The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with partnerships with Photys Therapeutics, Ascendis Pharma and two Flagship-backed start ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

On the last day of 2024, Lexington’s Valo Health Inc. also shared that its Phase 2 trial of OPL-0401 in patients with dia­bet­ic retinopa­thy did not meet its pri­ma­ry or sec­ondary end ...

NVO Expands Collaboration Agreement With Valo Health In the last press release, Novo Nordisk announced expanding its partnership with Valo, leveraging the latter’s extensive human dataset and ...

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...

With the expanded agreement, Novo will collaborate with Valo to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases. BY THE NUMBERS Under the ...